Opposite responses in two DNA repair capacity tests in lymphocytes of head and neck cancer patients

Journal of Applied Genetics

Volumn 43, Issue 4, 2002, Pages 525-534

  Sa̧siadek, Maria ^a   Schlade Bartusiak, Kamila ^a   Zych, Monika ^a   Noga, Leszek ^a   Czemarmazowicz, Halina ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Adaptive response; Bleomycin test; Diepoxybutane; DNA repair; HNSCC; Protective effect

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUTADIENE DIEPOXIDE; CARCINOGEN; EPOXIDE;

ARTICLE; CHROMOSOME ABERRATION; DNA REPAIR; DRUG EFFECT; GENETICS; HEAD AND NECK TUMOR; HUMAN; LYMPHOCYTE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SISTER CHROMATID EXCHANGE;

ANTINEOPLASTIC AGENTS; BLEOMYCIN; CARCINOGENS; CHROMOSOME ABERRATIONS; DNA REPAIR; EPOXY COMPOUNDS; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; SISTER CHROMATID EXCHANGE;

EID: 0036044234     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. ANKATHIL R., JOYTHISH B., MADHAVAN J., NAIR M.K. (1999). Deficient DNA repair capacity: a predisposing factor and high risk predictive marker in familial colorectal cancer. J. Exp. Clin. Cancer Res. 18: 33-37.
2. BERWICK M., VINEIS P. (2000). Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J. Natl. Cancer Inst. 92: 874-897.
3. BUKVIC N., GENTILE M., SUSCA F., FANELLI M., SERIO G., BUONADONNA L. CAPURSO A., GUANTI G. (2001). Sex chromosome loss, micronuclei, sister chromatid exchanges and aging: a study including 16 centenarians. Mutat. Res. 498: 159-167.
4. CLOOS J., STEEN I., JOENJE H., KO J.Y., DE VRIES N., VAN DER STERRE M.L.T., NAUTA J.J.P., SNOW G.B., BRAAKHUIS B.J.M. (1993). Association between bleomycin genotoxicity and non-constitutional risk factors for head and neck cancer. Cancer Lett. 74: 161-165.
5. D'ERRICO M., CALCAGNILE A., IAVARONE I., SERA F., BALIVA G., CHINNI L.M., CORONA R., PASQUINI P., DOGLIOTTI E. (1999). Factors that influence the DNA repair capacity of normal and skin cancer-affected individuals. Cancer Epidemiol. Biomarkers Prev. 8: 553-559.
6. DRESP J., SCHMID E., BAUCHINGER M. (1978). The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo. Mutat. Res. 56: 341-353.
7. FAN C.Y. (2001). Genetic alterations in head and neck cancer: interactions among environmental carcinogens, cell cycle control, and host DNA repair. Curr. Oncol. Rep. 3: 66-71.
8. FIREMAN Z., SHABTAI F., LURIE B. (1994). Chromosome sensitivity to bleomycin-induced mutagenesis in lymphocytes from colorectal cancer patients under 40 years of age. Dis. Colon Rectum 37: 1317-1320.
9. GOUKASSIAN D., GAD F., YAAR M., ELLER M.S., NEHAL U.S., GILCHREST B.A. (2000). Mechanisms and implications of the age-associated decrease in DNA repair capacity. FASEB J. 14: 1325-1334.
10. HENDRY J.H. (2001). Genomic instability: potential contributions to tumor and normal tissue response, and second tumors, after radiotherapy. Radiother. Oncol. 59: 117-126.
11. HSU T.C. (1987). Genetic predisposition to cancer with special reference to mutagen sensitivity. In Vitro Cell Devel. Biol. 23: 591-603.
12. HSU T.C., CHERRY L.M., SAMAAN L.A. (1985). Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet. Cytogenet. 17: 307-313.
13. HSU T.C., JOHNSTON D.A., CHERRY L.M., RAMKISSOON D., SCHANTZ S.P., JESSUP J.M., WINN R.J., SHIRLEY L., FURLONG C. (1989). Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int. J. Cancer 43: 403-409.
14. HULLA J.E., MILLER M.S., TAYLOR J.A., HEIN D.W., FURLONG C.E., OMIECINSKI C.J, KUNKEL T.A. (1999). Symposium overview: the role of genetic polymorphism and repair deficiencies in environmental disease. Toxicol. Sci. 47: 135-143.
15. JAŁOSZYŃSKI P., KUJAWSKI M., CZUB-ŚWIERCZEK M., MARKOWSKA J., SZYFTER K. (1997). Bleomycin-induced DNA damage and its removal in lymphocytes of breast cancer patients studied by comet assay. Mutat. Res. 385: 223-33.
16. JOYTHISH B., ANKATHIL R., CHANDINI R., VINODKUMAR B., NAYAR G.S., ROY D.D., MADHAVAN J., NAIR M.K. (1998). DNA repair proficiency: a potential marker for identification of high risk members in breast cancer families. Cancer Lett. 124: 9-13.
17. KRȨCICKI T., SCHLADE K., BLIN N., SA̧SIADEK M. (1997). Chromosome instability in head and neck cancer patients. Oncol. Rep. 4: 1383-1385.
18. LANDI S., FRENZILLI G., SBRANA I., BARALE R. (1996). Modulating factors of individual sensitivity to diepoxybutane: sister chromatid exchanges induced in vitro in human lymphocytes. Mutat. Res. 357: 75-82.
19. MICHALSKA J., MOTYKIEWICZ G., KALINOWSKA E., CHORA̧ŻY M. (1998). Bleomycin sensitivity test in the exposed and reference human populations. Mutat. Res. 418: 43-48.
20. MITELMAN F. (2000). Recurrent chromosome aberrations in cancer. Mutat. Res. 462: 247-253.
21. MOHRENWEISER H.W., JONES I.M. (1998). Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat. Res. 400: 15-24.
22. MUIR C., WEILAND L. (1995). Upper aerodigestive tract cancers. Cancer 75: 147-153.
23. NASCIMENTO P.A., DA SILVA M.A., OLIVEIRA E.M., SUZUKI M.F., OKAZAKI K. (2001). Evaluation of radioinduced damage and repair capacity in blood lymphocytes of breast cancer patients. Braz. J. Med. Biol. Res. 34: 165-176.
24. PAPADIMITRAKOPOULOU V.A. (2000). Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. Curr. Opinion Oncol. 12: 240-245.
25. PASQUINI R., SCASSELLATI-SFORZOLINI G., FATIGONI C., MARCARELLI M., MONARCA S., DONATO F., CENCETTI S., CERAMI F.M. (2001). Sister chromatid exchanges and micronuclei in lymphocytes of operating room personnel occupationally exposed to enfluorane and nitrous oxide. J. Environ. Pathol. Oncol. 20: 119-126.
26. RAJAEE-BEHBAHANI N., SCHMEZER P., RISCH A., RITTGEN W., KAYSER K.W., DIENEMANN H., SCHULZ V., DRINGS P., THIEL S., BARTSCH H. (2001). Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int. J. Cancer 95: 86-91.
27. ROY S.K., TRIVEDI A.H., BAKSHI S.R., PATEL S.J., SHUKLA P.H., BHATAVDEKAR J.M., PATEL D.D., SHAH P.M. (2000). Bleomycin-induced chromosome damage in lymphocytes indicates inefficient DNA repair capacity in breast cancer families. J. Exp. Clin. Cancer Res. 19: 169-173.
28. SA̧SIADEK M., PAPROCKA-BOROWICZ M. (1997). Correlation between the adaptive response and individual sensitivity to monoepoxybuten in in vitro experiments on human lymphocytes. Mutat. Res. 390: 239-243.
29. SPITZ M.R., FUEGER J.J., BEDDINGFIELD N.A., ANNEGERS J.F., HSU T.C., NEWELL G.R., SCHANTZ S.P. (1989). Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res. 49: 4626-4628.
30. SPITZ M.R., BONDY M.L. (1993). Genetic susceptibility to cancer. Cancer 72: 991-995.
31. STIERUM R.H., HAGEMAN G.J., VAN HERWIJNEN M.H., VAN DER VEER M.S., KLEINJANS J.C. (1997). Age-related negative associations between parameters of cytogenetic damage and ex-vivo (+/-) -anti-benzo(a)pyrene diolepoxide-induced unscheduled DNA synthesis in smoking humans. Cancer Epidemiol. Biomarkers Prev. 6: 943-948.
32. STURGIS E.M., CLAYMAN G.L., GUAN Y., GUO Z., WIE Q. (1999). DNA repair in lymphoblastoid cell lines from patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 125: 185-190.
33. TZANCHEVA M., KOMITOWSKI D. (1997). Latent chromosomal instability in cancer patients. Hum. Genet. 99: 47-51.
34. VOGEL U., DYBDAHL M., FRENTZ G., NEXO B.A. (2000). DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat. Res. 461: 197-210.
35. VOKES E.E., WEICHSELBAUM R.R., LIPPMAN S.M., HONG W.K. (1993). Head and neck cancer. N. Eng. J. Med. 328: 184-194.
36. WU X., GU J., PATT Y., HASSAN M., SPITZ M.R., BEASLEY R.P., HWANG L.Y. (1998). Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 7: 567-570.